Harrow Health, Inc. (HROW) News
Filter HROW News Items
HROW News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HROW News Highlights
- For HROW, its 30 day story count is now at 6.
- Over the past 18 days, the trend for HROW's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about HROW are DRUG, ACT and AMP.
Latest HROW News From Around the Web
Below are the latest news stories about Harrow Health Inc that investors may wish to consider to help them evaluate HROW as an investment opportunity.
Harrow Health to Announce Fourth Quarter and Year-End 2021 Financial Results on March 10, 2022NASHVILLE, Tenn., February 24, 2022--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2021, on Thursday, March 10, 2022, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Time to d |
Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100NASHVILLE, Tenn., February 22, 2022--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) filing for AMP-100, the Company’s drug candidate for ocular surface anesthesia and intraoperative pain management during ocular surgery. The FDA has assigned the application standard review and a Prescription Drug User Fee Act (PDUFA) target action date of October 16, 2022. |
Harrow Health to Present at Aegis Virtual ConferenceNASHVILLE, Tenn., February 15, 2022--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will present a company overview at the Aegis Capital Corp. Virtual Conference to be held on February 23-25, 2022. |
Two Insider Moonshots Rising on Sudden BuyingBiotech insiders are among the most important investors to pay close attention to. |
Harrow Health Publishes Corporate Transparency ReportNASHVILLE, Tenn., February 08, 2022--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that its inaugural 2022 Corporate Transparency Report is now available under the Investors section of the Company’s website, harrowinc.com. The report focuses on Harrow Health’s commitment to initiatives that it believes support its mission to make innovative, sight-saving medications more accessible and affordable. |
Harrow Health (NASDAQ:HROW) swells 13% this week, taking five-year gains to 236%Harrow Health, Inc. ( NASDAQ:HROW ) shareholders might understandably be very concerned that the share price has... |
Harrow Health to Participate in H.C. Wainwright BioConnect ConferenceNASHVILLE, Tenn., January 10, 2022--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the H.C. Wainwright BioConnect Conference to be held virtually on January 10-13, 2022. |
Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDANASHVILLE, Tenn., January 04, 2022--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first‑in‑class medicines for sedation and analgesia, today announced the filing of two investigational new drug applications (INDs) with the U.S. Food and Drug Administration (FDA) for two sublingual, IV-free, non‑opioid formulations – MELT-210 (midazolam) for procedural sedation and MELT-400 (ketamine) for pain. Both formulations have been developed in an exclusive partnership with |
Select Medical's (SEM) Rising Stake in Concentra to AidSelect Medical Holdings (SEM) acquires the remaining Concentra stake from equity holders for $625.6 million. |
Harrow Health (NASDAQ:HROW) Upgraded to “Buy” by Zacks Investment ResearchZacks Investment Research upgraded shares of Harrow Health (NASDAQ:HROW) from a hold rating to a buy rating in a report released on Monday morning, Zacks.com reports. Zacks Investment Research currently has $9.50 target price on the stock. According to Zacks, “Harrow Health Inc. owns a portfolio of healthcare businesses, including an ophthalmology pharmaceutical compounding business, […] |